DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: Cagrilintide
Drug: Semaglutide

First Posted Date: 2024-03-21

Last Posted Date: 2025-04-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 180

Registration Number: NCT06323174

Locations: 🇺🇸
Nat Res Inst Huntington Park, Huntington Park, California, United States
🇺🇸
Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸
Southern California Dermatology, Santa Ana, California, United States

and more 46 locations

A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

Completed

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD)
Systemic Inflammation
Chronic Kidney Disease (CKD)

Interventions: Other: No treatment given

First Posted Date: 2024-03-21

Last Posted Date: 2024-07-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 300

Registration Number: NCT06322641

Locations: 🇺🇸
KJT Group, Inc., Rochester, New York, United States

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Cagrilintide
Drug: Placebo
Drug: Semaglutide

First Posted Date: 2024-03-21

Last Posted Date: 2025-05-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 270

Registration Number: NCT06323161

Locations: 🇯🇵
Kumanomae Nishimura Internal Medical Clinic, Arakawa-ku, Tokyo, Japan
🇯🇵
Akaicho Clinic, Chiba-shi, Chiba, Japan
🇯🇵
Futata Tetsuhiro Clinic Meinohama, Fukuoka-shi, Fukuoka, Japan

and more 46 locations

A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Decitabine-THU

First Posted Date: 2024-03-04

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT06291285

Locations: 🇺🇸
ICON-Salt Lake City, Salt Lake City, Utah, United States
🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Cagrilintide
Drug: Semaglutide
Drug: Atorvastatin
Drug: Warfarin

First Posted Date: 2024-03-04

Last Posted Date: 2025-05-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT06289504

Locations: 🇨🇦
Altasciences Company Inc., Mount-Royal, Quebec, Canada

Prevalence and Economic Burden of Obesity-related Comorbidities in the Gulf Region: A Retrospective, Observational Study

Completed

Conditions: Obesity

Interventions: Other: No treatment given

First Posted Date: 2024-03-01

Last Posted Date: 2024-10-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1322

Registration Number: NCT06288399

Locations: 🇰🇼
Farwaniya Hospital, Farwaniya, Kuwait
🇰🇼
Al-Adan Hospital, Hadiya, Kuwait
🇰🇼
Al-Amiri Hospital, Kuwait City, Kuwait

and more 4 locations

A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting

Phase 1

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin icodec
Drug: Insulin degludec

First Posted Date: 2024-03-01

Last Posted Date: 2025-03-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT06288412

Locations: 🇦🇹
Medical University of Graz, Graz, Austria

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Conditions: Haemophilia B
Haemophilia A

Interventions: Drug: Concizumab

First Posted Date: 2024-02-29

Last Posted Date: 2025-04-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 23

Registration Number: NCT06285071

Locations: 🇯🇵
Kyushu university hospital_Pediatrics, Fukuoka, Japan
🇯🇵
Kagoshima City Hospital, Kagoshima, Japan
🇯🇵
St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa, Japan

and more 4 locations

A Research Study of a New Medicine (NNC0650-0013) in Healthy Men

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: NNC0650-0013 A
Drug: Placebo

First Posted Date: 2024-02-29

Last Posted Date: 2024-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 11

Registration Number: NCT06284798

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Completed

Conditions: Obesity

Interventions: Drug: Liraglutide

First Posted Date: 2024-02-28

Last Posted Date: 2025-04-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 300

Registration Number: NCT06283641

Locations: 🇨🇳
Changhua Christian Hospital, Changhua City, Taiwan
🇨🇳
HsinChu Municipal MacKay Children's Hospital, Hsinchu City, Taiwan
🇨🇳
HsinChu MacKay Memorial Hospital, Hsinchu City, Taiwan

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy